Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 4:8:e27.
doi: 10.15420/cfr.2022.06. eCollection 2022 Jan.

Epidemiology and Clinical Features of Heart Failure with Preserved Ejection Fraction

Kanako Teramoto  1 , Tiew-Hwa Katherine Teng  1   2   3 , Chanchal Chandramouli  1   3 , Jasper Tromp  1   3   4 , Yasuhiko Sakata  5 , Carolyn Sp Lam  1   3   6
Affiliations
Review

Epidemiology and Clinical Features of Heart Failure with Preserved Ejection Fraction

Kanako Teramoto et al. Card Fail Rev. .

Abstract

Heart failure (HF) with preserved ejection (HFpEF) constitutes a large and growing proportion of patients with HF around the world, and is now responsible for more than half of all HF cases in ageing societies. While classically described as a condition of elderly, hypertensive women, recent studies suggest heterogeneity in clinical phenotypes involving differential characteristics and pathophysiological mechanisms. Despite a paucity of disease-modifying therapy for HFpEF, an understanding of phenotypic similarities and differences among patients with HFpEF around the world provides the foundation to recognise the clinical condition for early treatment, as well as to identify modifiable risk factors for preventive intervention. This review summarises the epidemiology of HFpEF, its common clinical features and risk factors, as well as differences by age, comorbidities, race/ethnicity and geography.

Keywords: Heart failure with preserved ejection fraction; cluster analysis; comorbidities; epidemiology; prognosis; risk factors; sex differences.

PubMed Disclaimer

Conflict of interest statement

Disclosure: JT has received consultancy or speaker fees from Roche Diagnostics, Daiichi-Sankyo, Boehringer-Ingelheim and Us2.ai. CSPL has received research support from AstraZeneca, Bayer, Boston Scientific and Roche Diagnostics; has served as consultant or on advisory boards/steering committees/executive committees for Actelion, Alleviant Medical, Allysta, Amgen, ANaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma, EchoNous, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development, Medscape, Merck, Novartis, Novo Nordisk, Radcliffe Group, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics, Us2.ai and WebMD Global; and serves as co-founder and non-executive director of Us2.ai. All other authors have no conflicts of interest to declare. Funding: JT is supported by the National University of Singapore Start-Up grant and a Ministry of Education Tier 1 grant. CSPL is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore.

Figures

Figure 1:
Figure 1:. Common HFpEF Phenotypes Seen in Studies of Clustering Analysis.
Figure 2:
Figure 2:. Regional Characteristics of Patients with HFpEF
See this image and copyright information in PMC

References

    1. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263–71. doi: 10.1016/j.jacc.2013.02.092. - DOI - PubMed
    1. Shah SJ, Katz DH, Selvaraj S et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation. 2015;131:269–79. doi: 10.1161/CIRCULATIONAHA.114.010637. - DOI - PMC - PubMed
    1. Kao DP, Lewsey JD, Anand IS et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail. 2015;17:925–35. doi: 10.1002/ejhf.327. - DOI - PMC - PubMed
    1. Segar MW, Patel KV, Ayers C et al. Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis. Eur J Heart Fail. 2020;22:148–58. doi: 10.1002/ejhf.1621. - DOI - PubMed
    1. Hedman ÅK, Hage C, Sharma A et al. Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning. Heart. 2020;106:342–9. doi: 10.1136/heartjnl-2019-315481. - DOI - PubMed